Daiichi Sankyo at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Daiichi Sankyo takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8033. Its program centres on antibody-drug conjugates in breast and lung cancer, including the role of nurses in caring for patients with advanced breast cancer. It also covers identifying patients with non-small cell lung cancer through actionable gene changes, and treatment of extensive-stage small cell lung cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Daiichi Sankyo Tokyo, Japan | |
Japanese pharmaceutical company developing antibody-drug conjugates including trastuzumab deruxtecan and datopotamab deruxtecan. | Booth Exhibiting at Booth 8033 Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Sun Oct 25 18:30–20:00 Daiichi Sankyo - Patient Identification in NSCLC: 10 From Actionable Genomic Alterations to Emerging ADC Opportunities Lung & thoracic cancersBiomarkers & precision oncology Satellite Mon Oct 26 13:00–14:30 Daiichi Sankyo and MSD - Shaping the Future of ES-SCLC: Pioneering Treatment Strategies Lung & thoracic cancers |
Instantly find 20 buyers from Daiichi Sankyo
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction